faCellitate, a venture team of Chemovator GmbH, the internal business incubator of BASF, and a specialist in the development of polymeric surface coatings for cell culture consumables, announced today their first distribution agreements. “Fueled by the positive customer feedback on our first product line – BIOFLOAT, we quickly identified best-in-class partners to increase our global reach”, explains Dr. Veronique Schwartz, team leader of faCellitate. “Therefore, we are proud to have entered into a distribution agreement with Swift Analytical for the British cell biology and pharmaceutical market, as well as with CarlioBioTec for Italy and Labpanda for Hong Kong”, says Dr. Schwartz. “Throughout these collaborations we can reach more customers and strengthen our local presence. All three distributors are strong leaders in their regions with a well-established network of academic and pharmaceutical contacts. With these partnerships we are confident to provide our customers with the best service possible”, explains Dr. Schwartz further.
“In addition, we have signed a distribution agreement with Primacyt, a leading provider of primary cells and services for biomedical and cell biology research”, adds Dr. Simon Widmaier, business development manager of faCellitate. ”The BIOFLOATTM 96 well plates are an ideal addition for their cell culture product portfolio. This collaboration will enable us to reach a larger audience and provide a more personalized service for toxicological studies with primary liver cells. These agreements are a major step for faCellitate to strengthen its international distribution network”, summarizes Dr. Widmaier.
“In addition, we have signed a distribution agreement with Primacyt, a leading provider of primary cells and services for biomedical and cell biology research”, adds Dr. Simon Widmaier, business development manager of faCellitate. ”The BIOFLOATTM 96 well plates are an ideal addition for their cell culture product portfolio. This collaboration will enable us to reach a larger audience and provide a more personalized service for toxicological studies with primary liver cells. These agreements are a major step for faCellitate to strengthen its international distribution network”, summarizes Dr. Widmaier.
